BioLife Solutions and Repligen Merger Clears Key US Regulatory Hurdle

Key Facts

In a move reflecting the ongoing consolidation within the biotech sector, the proposed merger between BioLife Solutions and Repligen has cleared a significant regulatory hurdle. According to reports, the waiting period under the Hart-Scott-Rodino (HSR) Act has expired without a second request from regulators. This expiration is a mandatory step for antitrust clearance in the United States, effectively allowing the transaction to move toward its final closing stages.

This regulatory milestone is viewed as a key de-risking event for the announced merger, increasing the probability of successful deal completion. Per market data, BioLife Solutions (BLFS) shares closed at $34.93, while Repligen (RGEN) shares closed at $165.05 (as of September 9, 2026). The progress comes as market participants monitor the regulatory environment for healthcare and life sciences transactions.

Based on price levels at the close of September 9, 2026, RGEN has maintained a trading range between $162.46 and $169.52, while BLFS saw a daily high of $35.62. With no major upcoming sector-specific catalysts in the immediate economic calendar, investors will likely focus on subsequent corporate filings regarding the definitive closing date of the merger.